Form 4: Pfizer Executive Christoffel Boshoff Reports Acquisition of Stock Appreciation Rights

Executive Vice President Christoffel Boshoff reports the acquisition of stock appreciation rights (SARs) tied to Pfizer common stock.

Summary

• Christoffel Boshoff, an Executive Vice President at Pfizer Inc., filed a Form 4 on February 28, 2024, reporting transactions related to stock appreciation rights.
• On February 27, 2024, Boshoff acquired 161,160 stock appreciation rights (SARs) with an exercise price of $26.89, which will be settled in Pfizer common stock on February 27, 2029, subject to vesting requirements.
• Additionally, Boshoff acquired 142,400 stock appreciation rights (SARs) with an exercise price of $26.89, which will be settled in Pfizer common stock on February 27, 2031, subject to vesting requirements.
• Following these transactions, Boshoff directly owns 161,160 and 142,400 derivative securities.

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing. The acquisition of stock appreciation rights is generally viewed as a positive sign, aligning executive interests with shareholder value, but it's a routine event.

Positives

• The acquisition of stock appreciation rights aligns the executive's interests with the long-term performance of Pfizer's stock.

Future Outlook

The stock appreciation rights will be settled in shares of Pfizer common stock on the fifth and seventh anniversary of the grant date, subject to vesting requirements.

Industry Context

Stock appreciation rights are a common form of executive compensation in the pharmaceutical industry, aligning executive incentives with shareholder value.

Comparison to Industry Standards

• Companies like Johnson & Johnson (JNJ) and Merck & Co. (MRK) also utilize stock appreciation rights as part of their executive compensation packages.
• The vesting schedules and settlement terms are generally in line with industry practices.

Stakeholder Impact

• The acquisition of stock appreciation rights aligns the executive's interests with shareholders, potentially driving long-term value creation.

Key Dates